Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.

Publication Type:

Journal Article


The Lancet infectious diseases, Volume 11, Issue 4, p.284-92 (2011)


2011, Administration, Oral, Adolescent, Adult, Aged, Antiviral Agents, Benzimidazoles, Canada, Center-Authored Paper, Chemoprevention, Cytomegalovirus Infections, Double-Blind Method, Europe, Female, Humans, Male, Middle Aged, Placebos, Ribonucleosides, Stem Cell Transplantation, transplantation, Treatment Outcome, United States, Vaccine and Infectious Disease Division, Young Adult


Available drugs against cytomegalovirus have adverse effects that compromise their prophylactic use in recipients of allogeneic stem-cell transplants. We assessed the safety, tolerability, and antiviral activity of oral maribavir in such patients.